Parker Institute for Cancer Immunotherapy:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Parker Institute for Cancer Immunotherapy - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9390)・商品コード:DATA904C9390
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:29
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Parker Institute for Cancer Immunotherapy (Parker Institute), a subsidiary of The Parker Foundation is a nonprofit public benefit corporation which focuses on the development of immune therapies for the treatment of cancer. The institute coordinates together the scientists, nonprofits, academic institutions, biotechnology, and pharmaceutical industry partners to provide innovative services, tools and resources for new discoveries in cancer immunotherapy research. Its research focuses in the areas of T-cell therapies, tumor antigen discovery, tumor microenvironment and checkpoint blockade response. The institute works in collaboration with other research centers such as Memorial Sloan Kettering Cancer Center, Washington University School of Medicine, The University of Pennsylvania, Dana-Farber Cancer Institute, Stanford Medicine, and others. Parker Institute is headquartered in San Francisco, California, the US.

Parker Institute for Cancer Immunotherapy – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Parker Institute for Cancer Immunotherapy, Medical Devices Deals, 2012 to YTD 2018 9
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 12
Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 14
ImaginAb Raises USD7.7 Million in Venture Financing 16
Partnerships 17
Parker Institute for Cancer Immunotherapy Enters into Partnership with Xyphos Biosciences 17
Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 18
Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 19
Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Agreement 20
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 21
Parker Institute for Cancer Immunotherapy Enters into Agreement with PsiOxus Therapeutics 22
Parker Institute for Cancer Immunotherapy – Key Employees 23
Parker Institute for Cancer Immunotherapy – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Government and Public Interest 25
May 15, 2018: Penn Study Finds that Different Diseases Elicit Distinct Sets of Exhausted T Cells 25
Product News 26
Apr 10, 2017: Parker Institute researchers publish first major scientific paper in Nature 26
Mar 07, 2018: Parker Institute for Cancer Immunotherapy: The battle to tame autoimmunity 27
Mar 05, 2018: Predicting Childhood Leukemia Relapse Using Machine Learning 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Key Facts 2
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Parker Institute for Cancer Immunotherapy, Deals By Therapy Area, 2012 to YTD 2018 8
Parker Institute for Cancer Immunotherapy, Medical Devices Deals, 2012 to YTD 2018 9
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tmunity Therapeutics Raises Additional USD35 Million in Series A Venture Financing 12
Tmunity Therapeutics Raises USD100 Million in Series A Venture Financing 14
ImaginAb Raises USD7.7 Million in Venture Financing 16
Parker Institute for Cancer Immunotherapy Enters into Partnership with Xyphos Biosciences 17
Inovio Pharma and Parker Institute for Cancer Immunotherapy Enter into Agreement 18
Seres Therapeutics to Enter into Partnership Agreement with MD Anderson and Parker Institute 19
Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Agreement 20
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 21
Parker Institute for Cancer Immunotherapy Enters into Agreement with PsiOxus Therapeutics 22
Parker Institute for Cancer Immunotherapy, Key Employees 23

List of Figures
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Parker Institute for Cancer Immunotherapy, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Parker Institute for Cancer Immunotherapy, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Parker Institute for Cancer Immunotherapy:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9390)販売に関する免責事項を必ずご確認ください。
★調査レポート[Parker Institute for Cancer Immunotherapy:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆